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Abstract
Sarcoidosis is a complex disease of unknown etiology characterized by the presence of 
granulomatous inflammation. Though various immune system pathways have been implicated in 
disease, the relationship between the genetic determinants of sarcoidosis and other inflammatory 
disorders has not been characterized. Herein, we examined the degree of genetic pleiotropy 
common to sarcoidosis and other inflammatory disorders to identify shared pathways and disease 
systems pertinent to sarcoidosis onset. To achieve this, we quantify the association of common 
variant polygenic risk scores from nine complex inflammatory disorders with sarcoidosis risk. 
Enrichment analyses of genes implicated in pleiotropic associations were further used to elucidate 
candidate pathways. In European-Americans, we identify significant pleiotropy between risk of 
sarcoidosis and risk of asthma (R2=2.03%; p=8.89×10−9), celiac disease (R2=2.03%; 
p=8.21×10−9), primary biliary cirrhosis (R2=2.43%; p=2.01×10−10), and rheumatoid arthritis 
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(R2=4.32%; p=2.50×10−17). These associations validate in African Americans only after 
accounting for the proportion of genome-wide European ancestry, where we demonstrate similar 
effects of polygenic risk for African-Americans with the highest levels of European ancestry. 
Variants and genes implicated in European-American pleiotropic associations were enriched for 
pathways involving interleukin-12, interleukin-27, and cell adhesion molecules, corroborating the 
hypothesized immunopathogenesis of disease.
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Pleiotropy; sarcoidosis; immunopathogenesis; genetic risk; interleukin-12
Introduction
Genome-wide association (GWA) studies indicate that most variants underlying complex 
diseases are of modest effect size.1 As these implicated variants may confer risk to more 
than one clinical phenotype, identifying and characterizing pleiotropy between disorders is 
necessary to elucidate disease etiology in general,2 especially for inflammatory-related 
disorders that share pathophysiologic pathways.3 Polygenic risk scores (PRSs) have emerged 
as a method to assess shared genetic risk between phenotypes. For example, characterizing 
polygenic risk using thousands of variants in schizophrenia explained ~2% of the variation 
in a sample of cases with bipolar disorder.4 To better define the genetic architecture of 
sarcoidosis, a granulomatous inflammatory disease of unknown etiology, we sought to 
assess the degree of pleiotropic risk between nine well-studied inflammatory diseases and 
risk of sarcoidosis. This study was conducted in both European-American (EA) and African-
American (AA) individuals, the latter being an admixed population with genetic ancestral 
contributions from both Africa and Europe.5
Sarcoidosis affects people of all race-ethnicities and occurs at all ages.6 Based on a twin 
study in Danish and Finnish populations, the heritability of sarcoidosis was estimated to be 
0.66, confirming a strong genetic component for this disease.7 The pathophysiology of 
sarcoidosis involves a dysregulated immune reaction to an unknown antigen(s) that leads to 
granulomatous inflammation and organ dysfunction.6 While sarcoidosis most often affects 
the lungs in as many as 90% of cases, granulomas can occur in any organ, leading to 
considerable clinical variance.6, 8 In the United States, a significant disparity is observed in 
the prevalence and severity of sarcoidosis between AAs and EAs. One study estimated the 
annual incidence of sarcoidosis in EAs to be 10.9 cases per 100,000, but this value more 
than triples in AAs (35.5 cases per 100,000).9 In addition, AAs have more extra-thoracic 
involvement than EA sarcoidosis patients, are less likely to have resolving disease and are 
more likely to die from sarcoidosis than EA patients.10 The differences in clinical and 
epidemiological characteristics of these two groups are likely due to both environmental and 
genetic differences.9, 10 Across ethnicities, assessing the degree of shared polygenic risk of 
sarcoidosis and other genetically-characterized inflammatory disorders may aid in our 
understanding of this complex disease.
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To date, several putative sarcoidosis susceptibility genes have been revealed by linkage 
analyses,11 genome-wide association studies,12, 13 admixture mapping,14 Immunochip 
associations,13, 15 and targeted sequencing studies.16 Recent analyses of organ-specific 
manifestations of sarcoidosis have also identified genetic risk factors for sarcoidosis 
phenotypes. For example, novel genetic associations were implicated in sarcoidosis patients 
with Heerfordt’s syndrome (uveoparotid fever)17 and associated with clinical characteristics 
similar to Blau Syndrome (an autosomal dominant granulomatous inflammation of skin, 
eyes and joints).18 Additionally, organ-specific manifestations have been associated with 
genetic variation in sarcoid-related uveitis,19 cardiac,20 and neurosarcoidosis.16
Though these studies demonstrate specific genetic differences with respect to susceptibility 
and presence of specific clinical features, no prior study has broadly characterized the 
genome-wide polygenic risk in any sarcoidosis study sample or compared such profiles to 
other disorders. While the causal factors of sarcoidosis are largely unknown, the disease 
shares epidemiological, molecular, and immunological similarities (e.g. racial distribution, a 
strong effect at the human leukocyte antigen region, and involvement of various T-cell 
populations) with some autoimmune and inflammatory diseases. If the etiology of 
sarcoidosis indeed mimics other more extensively studied autoimmune disorders at a genetic 
level, we hypothesize that investigating known pathways and mechanisms of onset in 
analogous disease systems may bear new insights into this disorder. Thus, we aimed to 
identify specific disorders and implicate pathways in related inflammatory disease systems 
that share genetic determinants with sarcoidosis.
Results
We quantified the degree of pleiotropy between AA and EA sarcoidosis and nine other 
inflammatory disorders shown in Table 1. Using PRSice,21 we measured the associations of 
these other disease risk bases and the binary sarcoidosis clinical diagnosis in EA and AA 
individuals. A summary of these association models is shown in Figure 1. In EAs, 
sarcoidosis risk was associated with the polygenic risk of asthma, celiac disease, primary 
biliary cirrhosis, and rheumatoid arthritis disease, each of which explained 2% or more of 
the observed phenotypic variance (Table S3). While statistically significant, the PRSs for 
multiple sclerosis and type 1-diabetes models explained less than 1% of variance in 
sarcoidosis risk. In comparison, none of the complex inflammatory conditions were 
significantly associated with sarcoidosis disease status in AA under the standard PRS 
regression model (Table S2). However, when the modifying effect of proportion European 
genetic ancestry was accounted for, five disease bases (asthma, primary biliary cirrhosis, 
systemic lupus erythematous, type 1 diabetes, and ulcerative colitis) were associated with 
disease risk in AAs. The statistical significance of these models could be in part attributed to 
a multiplicative interaction term of the proportion of European admixture and the PRS 
(Table S5–S7).
In an effort to better assess polygenic overlap between our strongest associations, we show 
the variation explained at all variant thresholds for both ethnicities for asthma and primary 
biliary cirrhosis (Figure 2). In general, as the variant inclusion threshold became less 
stringent, the degree of variation explained increases before leveling off, an observation 
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consistent with other cross-phenotype polygenic associations.4, 22, 23 In models of 
sarcoidosis risk using two disease bases, the joint base of asthma and rheumatoid arthritis 
was the strongest (Table S8, S9), explaining 4.9% of the variance at the variant threshold p ≤ 
0.5. For EAs, our four most significant single disease models explain 2.0–4.3% of the 
variance in sarcoidosis risk. These values are consistent with, and in some cases surpass, the 
variance explained in previous analyses across phenotypes such as bipolar disorder and 
schizophrenia.4
To characterize the direction of the pleiotropic effects, Figure 3 shows the odds ratio (OR) of 
EA sarcoidosis cases and controls using polygenic risk scores, dichotomized at the median 
value, as the predictor. To compute ORs for AAs, we restricted the estimation to those in the 
top tertile of the proportion of European ancestry (individuals with > 0.194 European 
ancestry), which was comprised of 414 cases and 495 controls. The PRs were again used as 
the predictor, dichotomized at the median PRS of the high European ancestry subset. While 
higher PRSs for asthma, celiac disease, and primary biliary cirrhosis were associated with 
increased risk for sarcoidosis, the higher rheumatoid arthritis risk score group was associated 
with a protective effect. This result corroborates an epidemiologic finding that rheumatoid 
arthritis was the only inflammatory condition out of 12 examined that had a lower 
prevalence in a British cohort of 1,510 sarcoidosis cases compared to the general 
population.24
After identifying the disorders that share significant genetic risk with sarcoidosis, we sought 
to examine the genes implicated in the pleiotropic associations. Utilizing the 225,166 
variants shared between the five disease sets, we identified 238 common variants 
significantly associated (FDR < 0.05) with pleiotropy between sarcoidosis, asthma, celiac 
disease, primary biliary cirrhosis, and rheumatoid arthritis in the EA sample using the GPA 
framework.25 Using the 238 significant variants from the GPA model, we annotated 85 
unique genes (Table S10) using WebGestalt26 before searching for enriched pathway-based 
sets using ConsensusPathDB.27 Table 2 lists the seven pathways whose members were 
enriched (FDR < 0.05) in the list of genes implicated in more than one condition (Table 
S10). These pathways highlight established risk genes characterized in Th1 response in 
granulomatous tissue, such as interleukin-1228 and interleukin-27,29 while verifying the 
importance of T-cells and natural-killer cells,30 previously implicated in the pathogenesis of 
sarcoidosis using other molecular biology techniques.
Of the nine inflammatory diseases, our analyses failed to identify significant shared genetic 
risk associated with AA sarcoidosis when European ancestry was not accounted for. While 
the most direct way to compare the genetic risk bases between ethnic groups is to compute 
PRSs within each ethnicity and apply then apply them across ethnicities, the limited sample 
sizes limits the inferences of these resulting models. Nevertheless, we computed PRSs and 
applied them cross-ethnically (Table S4). Where the EA PRS was not associated with AA 
sarcoidosis risk at any variant threshold under the standard PRS model, the AA sarcoidosis 
base was significantly associated with EA sarcoidosis risk (p=0.020, R2=0.34%). 
Additionally, the inclusion of the context dependent effect of genome-wide European 
ancestry in the AA PRS model yielded a statistically significant association with the EA 
sarcoidosis base (p=0.0011 R2=0.79%) (Table S6). Though relatively few overlapping 
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variants from GWA studies of sarcoidosis have been identified between European and 
African ethnicities,31, 32 increasing the sample sizes of our sarcoidosis cohorts and refining 
the population samples based on the proportion of admixture could elucidate the degree of 
similar polygenic risk between ethnicities of sarcoidosis as well as pleiotropy with other 
conditions.
Discussion
While our study was able to identify novel evidence of pleiotropy between inflammatory 
conditions and sarcoidosis in the context of genome-wide European ancestry, our PRS 
approach could be enhanced by polygenic risk bases derived from studies with more 
ancestral diversity. Though the asthma meta-analysis results were from three ethnic groups, 
the other eight inflammatory risk bases were derived from individuals solely of European 
ancestry. A more exhaustive analytical approach would utilize summary statistics derived 
from studies of individuals with African ancestry in addition to those derived from 
Europeans. Our study thus is limited due to the lack of ethnic diversity present in these large 
genetic association studies. In order to best characterize the etiology of sarcoidosis and other 
complex traits, future sequencing studies such as the Precision Medicine Initiative must 
incorporate greater patient ethnic diversity, a “promise yet to be fulfilled” by the National 
Institutes of Health.33 Our results demonstrate the need and probable utility for performing 
genetic mapping studies in admixed and minority populations as a means to characterize the 
genetic risk basis of complex disorders.
An initial interpretation of our findings suggests that genetic risk to sarcoidosis may partially 
comprise different variants between ethnic populations. However, these differences could 
also be explained by the design of the genotyping platforms, the variability in LD structure 
between populations, and the limitations of the PRS algorithm. Due to the short 
recombination history of the European population relative to the African population, the 
overrepresentation of subjects of predominantly European ancestry in prior genetic 
association studies, as well as the historical bias in genotyping arrays designed to capture 
common genetic variation present in populations of European ancestry,34 the variants 
included in the summary statistics were more likely to tag causal variants in European 
populations. While recent methodological advancements such as LDPred have integrated LD 
structure into PRS models using Bayesian models,35 the behavior of these associations has 
not been well characterized in AA and other admixed populations due to the absence of 
genetic information. The lack of methodological development and characterization of 
behavior of genetic risk in admixed populations can again be partially attributed to the lack 
of genetic diversity available from publically funded genetic association studies. As such, we 
used PRSice as a primary association tool to compute our models as this method primarily 
provides a wrapper for the canonical PRS approach employed in prior studies4 and more 
extensively reviewed.39
From clinical coincidences,24 previous genome-wide association studies,12, 13 and our 
present work, evidence of a shared etiology between sarcoidosis and certain autoimmune 
disorders has been hypothesized. We suggest that pleiotropy between clinical characteristics 
of sarcoidosis and these associated inflammatory conditions could lead to novel disease 
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categories as has been demonstrated in other inflammatory conditions. For example, 
pleiotropic analyses of inflammatory bowel disease and primary sclerosing cholangitis 
suggest that comorbidity between these conditions may be a distinct disorder.3 For our 
purposes, clinical reports have linked celiac disease to sarcoidosis, including one celiac 
patient who experienced a reoccurrence of erythema nodosum after being exposed to wheat 
flour, leading the authors to hypothesize a causal relationship between celiac disease and 
sarcoidosis in some patients.36, 37 The statistically significant association between polygenic 
risk of celiac disease and EA sarcoidosis supports this hypothesis of a common causal agent 
in a subset of patients, which provides a unique avenue to examine the clinical variation of 
patients in the context of genetic risk.
While the utilization of the PRS algorithm across disorders has been widely implemented in 
other phenotypes, our study is the first to employ this methodology in the context of 
sarcoidosis and extend the analyses using GPA to identify candidate pathways shown in 
Table 2. A prominent genetic effector in our enriched pathways is interleukin-12 (IL-12), 
which is an established biomarker in active pulmonary sarcoidosis.28 In the hypothesized 
immunopathogenesis of sarcoidosis, antigen presenting cells are thought to secrete IL-12 in 
response to interactions with T-cells.6 IL-12 has also been shown to modulate the efficacy of 
glucocorticoid response in asthma,38 supporting our analyses that suggest a shared genetic 
risk basis may be active in both sarcoidosis and asthma—the principally pulmonary diseases 
considered in our analyses. We hypothesize that further analyses characterizing the 
pleiotropic mechanisms between asthma and sarcoidosis, particularly in the context of IL-12 
signaling, may explain some of the variation in clinical features, such as pulmonary severity 
and steroid response efficacy in these two disorders.
Overall, our discovery of significant pleiotropy between these inflammatory conditions and 
sarcoidosis provides another perspective on over a half-century of clinical and 
epidemiological findings into the etiology of this enigmatic condition. In particular, we 
provide evidence that the inflammatory signaling pathways mediated by IL-12, IL-27, and 
cell adhesion molecules may be causal in multiple conditions in a subset of patients, 
providing unique opportunities to measure clinical outcomes from an individual’s genetic 
risk. Our results suggest that these genes and pathways may also been relevant to the 
presentation of pulmonary phenotypes in asthma and sarcoidosis. Future studies that 
measure the pleiotropic risk of sarcoidosis and other phenotypes, including other pulmonary 
and infectious diseases, may further elucidate candidate pathways for characterizing the 
pathogenesis of this and other disorders.
Materials and Methods
Our genetic samples comprised 2,738 self-identified AAs (1,273 sarcoidosis cases and 1,465 
controls) and 2,726 self-identified EAs (442 sarcoidosis cases and 2,284 controls) genotyped 
using the Illumina HumanOmni1-Quad array for ~1.1M variants across the genome under 
standard quality control measures as previously described.12 As the genotyping data used for 
the sarcoidosis populations were the exact same as those resulting from the quality control 
described in this prior manuscript,12 details of these steps are excluded from the present 
manuscript. We note that 1,945 of the 2,284 EA controls were obtained from external studies 
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that do not overlap with the samples used to generate the summary statistics for the other 
inflammatory disorders. Since the power of PRS increases as the base sample size 
increases,39 we used disease base sets for nine complex inflammatory disorders from large 
meta-analyses (Table 1). Each of these meta-analyses exceeded 10,000 combined cases and 
controls (average > 20,000). Summary statistics for eight of the inflammatory disorders were 
downloaded from either IBDgenetics.org or Immunobase.org in publically available 
repositories. The exception was the asthma study, where the EVE asthma meta-analysis 
consortium provided the results.40 While the asthma meta-analysis summarizes cases of 
European (39.5%), African (29.1%), and Latino (31.4%) ancestry, the other eight meta-
analyses contained samples of only European ancestry.
To compute polygenic risk scores, we used PRSice21 with the default fastscore parameters, 
which includes p-value informed linkage disequilibrium (LD) clumping with a cutoff of R2 
= 0.1, a 250kb distance threshold, and base variant thresholds of p = 10−4, 0.05, 0.1, 0.2, 0.3, 
0.4, and 0.5. We emphasize that the LD-clumping step considers the population substructure 
only in the target genotyping data, and the clumping technique has been successfully applied 
under similar analysis conditions in associating across disorders.22, 23 PRSice computes a 
risk score for each individual in the target set (in this case, our AA or EA sarcoidosis 
sample) using the summary statistics of variants from an independent GWA analysis base (in 
this case, each of the nine inflammatory diseases). These scores are regressed against the 
case/control status in the target sample to quantify the phenotypic variation explained by the 
polygenic risk across disorders. Though previously published PRS variant significance 
thresholds have ranged from p=0.5 to p=2 ×10−28, less-stringent variant p-value thresholds 
often produce models that explain a higher proportion of trait variance.4, 39
The summary statistic disease bases consisted of association results for genome-wide 
autosomal markers including the major histocompatibility complex (MHC) for each of the 
nine inflammatory disorders except celiac disease, where the MHC was not made available. 
While the genotyping platforms varied within and between studies, a minimum of 245,000 
(average >518,000) variants overlapped between the summary statistics and the sarcoidosis 
samples before LD-clumping and p-value thresholding (Table S1). Using a threshold of 
p=0.5, we tested the association between PRSs and case/control status in both the EA and 
AA sarcoidosis samples. In the AAs, we performed additional regression analyses including 
a multiplicative interaction term between PRS and genome-wide proportion European 
ancestry to assess the possibility of a modifying effect of genetic ancestry (see Supplemental 
PDF). In these models, the Nagelkerke’s adjusted-R2 and corresponding significance 
correspond to a full model, containing the main effect of PRS and proportion of European 
ancestry as well as the interaction term. Individual admixture estimates were computed 
using LAMP41 as we’ve previously described.14
As the polygenic risk methodology provides a measure of the association between disorders 
(i.e. pleiotropy), we performed additional analyses to target the individual pathways and 
genetic effectors implicated from the associations between diseases. To achieve this, we used 
the Genetic analysis incorporating Pleiotropy and Annotation (GPA) methodology, which 
increases statistical power needed to identify individual risk variants through joint analysis 
of multiple phenotypes.25 GPA uses an integrated probabilistic model that assigns a new 
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measure of statistical significance for each variant to a phenotype of interest (in this case, 
sarcoidosis) in the context of associations to other phenotypes (four other disease bases).25 
Notably, as the MHC was excluded from the celiac disease summary statistics, variants in 
this region were excluded from the pleiotropic analysis. As only 3 of the 225,166 were 
statistically significant (FDR < 0.05) using only the sarcoidosis summary statistics, GPA was 
able to uncover many associations underpowered in single phenotype associations. After 
identifying shared genetic variants associated with risk of sarcoidosis and other phenotypes, 
we annotated statistically significant variants to their corresponding genes using 
WebGestalt26 before searching for enriched pathway-based sets using ConsensusPathDB.27 
Gene sets enriched highlight shared biologic pathways associated with risk of sarcoidosis 
and other inflammatory disorders. A complete graphical summary of the relationship 
between the methods, data, figures, tables, and other outputs is shown in Figure 4. Namely, 
summary statistics from external GWAS studies coupled with the sarcoidosis genotyping 
data are sufficient inputs to replicate the results using the tools indicated in this figure.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Summaries for PRS associations with sarcoidosis risk in the (A) European-Americans, (B) 
African-Americans samples, and (C) African-Americans accounting for the modifying effect 
of European ancestry. A variant including threshold of PT = 0.5 was used and the major 
histocompatibility complex was included where available. The Nagelkerke’s pseudo-R2 term 
and significance of model were calculated using PRSice21 for panels (A) and (B) and a 
likelihood ratio test for (C) (see Supplement) using nine inflammatory conditions as a 
prediction base: asthma (AS), Crohn’s disease (CD), celiac disease (CEL), multiple sclerosis 
(MS), primary biliary cirrhosis (PBC), rheumatoid arthritis (RA), systemic lupus 
erythematous (SLE), type 1 diabetes (T1D), and ulcerative colitis (UC).
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Figure 2. 
Nagelkerke’s pseudo-R2 value summaries of the association between risk scores derived 
from the two most significant inflammatory associations using seven significance thresholds 
and sarcoidosis. Asthma was used as the polygenic risk base associated with (A) EA 
sarcoidosis and (C) AA sarcoidosis modified by European ancestry. Primary biliary cirrhosis 
(PBC) was used as the polygenic risk base associated with (B) EA sarcoidosis and (D) AA 
sarcoidosis modified by European ancestry.
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Figure 3. 
Odds ratios summarizing the magnitude and direction of the association of significant PRSs 
with sarcoidosis risk by ethnicity. Estimates of the odds ratio with 95% confidence interval 
are shown comparing EA cases and controls dichotomized at the median polygenic risk 
score from four conditions: asthma (AS), celiac disease (CEL), primary biliary cirrhosis 
(PBC), and rheumatoid arthritis (RA). The odds ratios for the same four disorders were 
computed in the AAs after restricting the sample to the upper tertile of European ancestry, 
which comprised 414 cases and 495 controls. The PRS in this stratum was again 
dichotomized at the median to compute the corresponding odds ratios.
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Figure 4. 
A graphical overview of the data and methods used to produce data, tables, and figures for 
this manuscript. Files are indicated by the folded corner whereas methods (such as GPA and 
PRSice) are indicated in diamonds.
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Table 1
List of summary statistics case/control count and corresponding reference from original association study for 
nine inflammatory disorders used as prediction bases in this study. Further details of these studies are 
contained in the corresponding references.
Disease # Cases # Controls Study Population Ancestry Reference
Asthma 5,380 5,519 European, African, Hispanic 40
Celiac Disease 4,533 10,750 European 42
Crohn’s Disease 5,956 21,770 European 43
Multiple Sclerosis 9,772 17,376 European 44
Primary Biliary Cirrhosis 2,764 10,475 European 45
Rheumatoid Arthritis 5,539 20,169 European 46
Systemic Lupus Erythematous 7,219 15,991 European 47
Type 1 Diabetes 7,514 9,045 European 48
Ulcerative Colitis 6,968 21,770 European 43
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Table 2
Significant pathways enriched from the pleiotropic associations between sarcoidosis, asthma, celiac disease, 
primarily biliary cirrhosis, and rheumatoid arthritis. The statistical significance of 225,116 variants 
overlapping between these five risk bases was measured using GPA,25 and 238 significant variants (FDR < 
0.05) were mapped to 83 unique genes using WebGestalt.26 Enriched pathway-based sets were determined 
using ConsensusPathDB27 for these 83 genes, leading to the seven statistically significant (FDR < 0.05) 
pathways shown in the table. Each pathway has a corrected (FDR) and uncorrected (P-value) measure of 
significance of the overrepresentation of genes in the pathway from the 83 mapped genes. The MHC region 
was not included in the 225,116 overlapping variants as these were excluded from the celiac disease summary 
statistics.
Enriched pathway-based set Source P-value FDR
IL-12 signaling INOH 0.00033 0.0134
Nef and signal transduction Reactome 0.00044 0.0134
No2-dependent IL-12 pathway in NK cells BioCarta 0.00056 0.0134
IL-12 and STAT4 dependent signaling pathway in Th1 Development BioCarta 0.0016 0.0289
Cell adhesion molecules KEGG 0.00247 0.0334
T-Cell Receptor (TCR) NetPath 0.00278 0.0334
IL-27-mediated signaling events PID 0.00483 0.0497
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